(Q35187352)

7 August 2017

Early intervention in multiple sclerosis : better outcomes for patients and society? (English)

1 reference

7 August 2017

0 references

Peter Flachenecker

1

1 reference

PubMed ID

12887260

7 August 2017

Peter Rieckmann

series ordinal

2

1 reference

7 August 2017

1 January 2003

1 reference

7 August 2017

1 reference

7 August 2017

63

1 reference

7 August 2017

15

1 reference

7 August 2017

1525-1533

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200363150-00001

7 August 2017

0 references

cites work

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadi

1 reference

12 December 2020

Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results

1 reference

12 December 2020

Final analysis of the European multicenter trial on IFNbeta-1b in secondary-progressive MS

1 reference

12 December 2020

Cost and health related quality of life consequences of multiple sclerosis

1 reference

12 December 2020

Prevalence, expenditures, utilization, and payment for persons with MS in insured populations.

1 reference

12 December 2020

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

12 December 2020

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group

1 reference

12 December 2020

Defining the clinical course of multiple sclerosis: Results of an international survey

1 reference

12 December 2020

Detection of ventricular enlargement in patients at the earliest clinical stage of MS

1 reference

12 December 2020

A cost-utility analysis of interferon beta for multiple sclerosis

1 reference

12 December 2020

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

1 reference

12 December 2020

The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability

1 reference

12 December 2020

Cost-effectiveness analysis of interferon beta in multiple sclerosis: a Markov process analysis

1 reference

12 December 2020

Escalating immunotherapy of multiple sclerosis.Austrian-German- Swiss Multiple Sclerosis Therapy Consensus Group [MSTCG]

1 reference

12 December 2020

Population based cost utility study of interferon beta-1b in secondary progressive multiple sclerosis

1 reference

12 December 2020

1 reference

12 December 2020

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

12 December 2020

Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group

1 reference

12 December 2020

Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group

1 reference

12 December 2020

Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study

1 reference

12 December 2020

PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS.

1 reference

12 December 2020

1 reference

12 December 2020

Cost-utility analysis of interferon beta-1b in secondary progressive multiple sclerosis

1 reference

12 December 2020

Economic evaluation of health care technologies

1 reference

12 December 2020

Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results

1 reference

12 December 2020

Early intervention with immunomodulatory agents in the treatment of multiple sclerosis

1 reference

12 December 2020

Cost-utility of interferon beta1b in the treatment of patients with active relapsing-remitting or secondary progressive multiple sclerosis.

1 reference

12 December 2020

Consensus statement of the Canadian MS CLinics Network on: the use of disease modifying agents in multiple sclerosis

1 reference

12 December 2020

Cost-utility analysis of interferon beta-1B in secondary progressive multiple sclerosis using natural history disease data.

1 reference

12 December 2020

Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS

1 reference

12 December 2020

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

12 December 2020

Guidelines for using quantitative measures of brain magnetic resonance imaging abnormalities in monitoring the treatment of multiple sclerosis

1 reference

12 December 2020

Use of interferon beta in multiple sclerosis: rationale for early treatment and evidence for dose- and frequency-dependent effects on clinical response

1 reference

12 December 2020

Axonal transection in the lesions of multiple sclerosis

1 reference

12 December 2020

Escalating immunomodulatory therapy of multiple sclerosis. 1st supplement: December 2000

1 reference

12 December 2020

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

1 reference

12 December 2020

The costs of multiple sclerosis: a cross-sectional, multicenter cost-of-illness study in Italy

1 reference

12 December 2020

Quality of life and cost of multiple sclerosis

1 reference

12 December 2020

Costs, quality of life and disease severity in multiple sclerosis: a cross-sectional study in Sweden.

1 reference

12 December 2020

Economic Evaluation of Multiple Sclerosis in the UK, Germany and France

1 reference

12 December 2020

Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines

1 reference

12 December 2020

10.2165/00003495-200363150-00001

Identifiers

DOI

1 reference

PubMed ID

12887260

Dimensions Publication ID

7 August 2017

0 references

1 reference

PubMed ID

12887260